Hepatitis A
📧 Sign up to get email alerts when something new happens for Hepatitis A.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Twinrix Adult (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.
Twinrix Adult (hepatitis A virus inactivated + hepatitis B surface antigen) has been authorised for use in adults by the EMA.
-
EMA approval · 2026-08-03EMA Authorised: Twinrix Paediatric (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.
The EMA has authorised Twinrix Paediatric, a combined hepatitis A and B vaccine for children, under the marketing authorization holder Glaxo…
-
EMA approval · 2026-08-03EMA Authorised: Ambirix (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.
Ambirix, a vaccine containing inactivated hepatitis A virus and hepatitis B surface antigen, has been authorised for immunization against he…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis [NA]
This clinical trial compares oral ursodeoxycholic acid for reducing bilirubin levels in patients with acute viral hepatitis and is currently…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis
This clinical trial evaluates hepatitis A immunity and the immunogenicity of a single-dose HAV vaccine in patients with cirrhosis; the study…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This clinical trial update examines five-year antibody persistence after vaccination with IPV, MMR, and HepA-L vaccines. The study is not ye…
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People [Phase 4]
Phase 4 trial evaluating the immunogenicity and safety of an inactivated Hepatitis A vaccine in HIV-infected individuals.
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Clinical trial update on the long-term immunogenicity of the L-HAV Hepatitis A vaccine in healthy Thai children and adolescents. The study s…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV [Phase 3]
This Phase 3 clinical trial update describes the immunogenicity and safety evaluation of the investigational hepatitis A vaccine I-HAV in he…
-
CLINICAL_TRIALS trial_result · 2025-05-22Clinical Trial Update: To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) [Phase 3]
Phase 3 trial update reporting immunogenicity and safety data for the inactivated Hepatitis A vaccine VITHA-A.
-
CLINICAL_TRIALS trial_result · 2025-05-04Clinical Trial Update: Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents [Phase 3]
This Phase 3 clinical trial update reports on the immunogenicity and safety of both inactivated and live-attenuated hepatitis A vaccines in …
-
CLINICAL_TRIALS research · 2025-04-27Clinical Trial Update: Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
A prospective cohort study investigating immune checkpoint inhibitor–induced hepatitis in cancer patients; currently recruiting.
-
CLINICAL_TRIALS other · 2025-04-24Clinical Trial Update: Immunity With Acute Hepatits A
A clinical trial update from Assiut University investigates immunity in acute Hepatitis A. The study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: Effects of Aging on Primary and Secondary Vaccine Responses [Phase 1]
A completed Phase 1 Stanford study examines how aging affects primary and secondary vaccine responses to vaccines for influenza and hepatiti…
-
CLINICAL_TRIALS trial_result · 2024-12-05Clinical Trial Update: PCV13 + Hepatitis A Vaccine for Adults [Phase 4]
A Phase 4 trial completed, assessing immune responses to Prevnar 13 and a Hepatitis A vaccine in adults. The study measured immune response …
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23)
Clinical trial protocol update for Access Anti-HAV and Access Anti-HAV IgM assays in Europe (HAV-EU-11-23) sponsored by Beckman Coulter; the…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old [Phase 4]
Phase 4 trial evaluating immunogenicity and safety of a Hepatitis A vaccine in adults 18-50; sponsor Sinovac Biotech; status Active Not Recr…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children [Phase 4]
A Phase 4 trial evaluating the immunogenicity of an inactivated Hepatitis A vaccine in infants and young children has completed.
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: Phase IV Study of Concomitant Administration of the sIPV and HepA [Phase 4]
Phase IV trial update evaluating concomitant administration of Sabin Inactivated Poliovirus Vaccine (sIPV) and Hepatitis A vaccine; status i…
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis [Phase 4]
Phase 4 trial update evaluating efficacy and durability of hepatitis A vaccination in patients with advanced fibrosis and cirrhosis.
-
EMA approval · 2024-02-08EMA Authorised: Ambirix (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.
Ambirix has been authorised for immunization against hepatitis A and hepatitis B infections.
-
EMA approval · 2024-02-07EMA Authorised: Twinrix Paediatric (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.
EMA authorised Twinrix Paediatric, a hepatitis A and hepatitis B combination vaccine for paediatric use.
-
EMA approval · 2024-02-07EMA Authorised: Twinrix Adult (hepatitis A virus (inactivated);hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.
Twinrix Adult has been authorised by the EMA for hepatitis A and hepatitis B immunization.
-
CLINICAL_TRIALS research · 2023-12-28Clinical Trial Update: Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination. [Phase 4]
A Phase 4 clinical trial update reports on the persistence of hepatitis A antibody in healthy adults roughly 32 years after vaccination.
-
CLINICAL_TRIALS research · 2023-10-10Clinical Trial Update: The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines [Phase 4]
Phase 4 trial assessing immunogenicity and safety of inactivated and live attenuated Hepatitis A vaccines.